Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Filings indexed 678 across all filing types
Latest filing 2025-05-20 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings
2025-05-20 English
Record Date
Regulatory Filings
2025-05-20 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation on Q4FY25 Financial Results' and is addressed to stock exchanges pursuant to SEBI regulations. It contains detailed financial highlights, including quarterly and full fiscal year data for FY25, with consolidated and segment-wise P&L figures, margins, and business updates. The content is typical of an investor presentation focusing on financial results and business strategy. It is not a full annual or quarterly report, audit report, or earnings release announcement but a detailed presentation for investors. The document length is substantial (15,000 characters), indicating it is the presentation itself, not just an announcement or a brief summary. Therefore, the appropriate classification is Investor Presentation (IP).
2025-05-20 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 20, 2025, announcing the Q4 FY25 financial results of Gland Pharma Limited. It includes detailed quarterly and annual financial data, management commentary on performance, business highlights, and dividend recommendations. The document references the fiscal period ending March 31, 2025, and provides comprehensive financial metrics such as revenue, EBITDA, PAT, margins, and segment performance. It is explicitly titled as a 'Press Release on Q4FY25 Financial Results' and contains substantive financial data and analysis rather than just a summary or announcement of a report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights. FY 2025
2025-05-20 English
Outcome of Board Meeting
Regulatory Filings
2025-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges informing them about the schedule of upcoming analyst and institutional investor meetings. It references regulatory compliance (SEBI Listing Obligations) and provides dates and types of meetings. The content is an announcement of meetings rather than a financial report, earnings release, or detailed investor presentation. It does not contain financial data, management discussion, or voting results. The document length is short (1635 characters), and it serves as an informational notice about scheduled meetings with investors and analysts. Therefore, it fits best under Investor Presentation (IP) category as it relates to investor engagement activities, but since it is only a schedule notice and not a detailed presentation, the closest appropriate category is Regulatory Filings (RNS) as a general regulatory announcement about investor meetings.
2025-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.